Abstract | BACKGROUND: METHODS: Patients received the first-line treatment of 180 mg rezivertinib orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the objective response rate (ORR) assessed by blinded independent central review (BICR). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: From Jun 12, 2019, to Oct 17, 2019, 43 patients were enrolled. At the data cutoff date on Dec 23, 2021, the ORR by BICR was 83.7% (95% CI: 69.3-93.2%). The median DoR was 19.3 (95% CI: 15.8-25.0) months. The median PFS by BICR was 20.7 (95% CI: 13.8-24.8) months and 22.0 (95% CI: 16.8-26.3) months by investigators. Data on OS was immature. Totally, 40 (93.0%) patients had at least one treatment-related adverse event while 4 (9.3%) of them were grade ≥ 3. CONCLUSIONS:
Rezivertinib (BPI-7711) showed promising efficacy and a favorable safety profile for the treatment among the locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation in the first-line setting. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03386955.
|
Authors | Yuankai Shi, Jianying Zhou, Yanqiu Zhao, Bo Zhu, Liangming Zhang, Xingya Li, Jian Fang, Jianhua Shi, Zhixiang Zhuang, Sheng Yang, Donglin Wang, Huiqing Yu, Longzhen Zhang, Rongsheng Zheng, Michael Greco, Tingting Wang |
Journal | BMC medicine
(BMC Med)
Vol. 21
Issue 1
Pg. 11
(01 08 2023)
ISSN: 1741-7015 [Electronic] England |
PMID | 36617560
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022. The Author(s). |
Chemical References |
- Antineoplastic Agents
- Protein Kinase Inhibitors
- ErbB Receptors
- EGFR protein, human
|
Topics |
- Humans
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics)
- Lung Neoplasms
(drug therapy, genetics)
- Antineoplastic Agents
(adverse effects)
- Protein Kinase Inhibitors
(adverse effects)
- ErbB Receptors
(genetics, therapeutic use)
- Mutation
|